SAB Biotherapeutics, Inc. (SABSW) stock
SABSWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABS
$0.01+0.00 (+33.33%)
Close on Oct 20, 2026Market cap $304.80MP/E –Yield –
SAB Biotherapeutics net income
Net income is the profit left for shareholders after every expense, interest and tax.
SAB Biotherapeutics's net income for the twelve months ending Jun 30, 2026 was -$12.78M. For fiscal 2025 it was $13.27M. The highest annual figure on record is $20.12M in fiscal 2020.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.27M | – |
| FY2024 | Dec 31, 2024 | -$34.11M | – |
| FY2023 | Dec 31, 2023 | -$42.19M | – |
| FY2022 | Dec 31, 2022 | -$18.74M | – |
| FY2021 | Dec 31, 2021 | -$17.14M | -185.2% |
| FY2020 | Dec 31, 2020 | $20.12M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$22.49M | – |
| Q1 FY2026 | Mar 31, 2026 | -$18.87M | – |
| Q4 FY2025 | Dec 31, 2025 | -$16.86M | – |
| Q3 FY2025 | Sep 30, 2025 | $45.45M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.11M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.20M | – |
| Q4 FY2024 | Dec 31, 2024 | -$11.39M | – |
| Q3 FY2024 | Sep 30, 2024 | -$10.35M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.34M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.03M | – |
| Q4 FY2023 | Dec 31, 2023 | -$22.86M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.10M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.88M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.35M | -845.9% |
| Q4 FY2022 | Dec 31, 2022 | -$7.87M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.08M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.78M | – |
| Q1 FY2022 | Mar 31, 2022 | $985.86K | -30.1% |
| Q4 FY2021 | Dec 31, 2021 | -$11.55M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.06M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.94M | – |
| Q1 FY2021 | Mar 31, 2021 | $1.41M | – |